ORAI1 Antibody - #DF7956

(1)   (8)  
Product: ORAI1 Antibody
Catalog: DF7956
Description: Rabbit polyclonal antibody to ORAI1
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 50 kDa,60kDa; 33kD(Calculated).
Uniprot: Q96D31
RRID: AB_2841354

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(92%), Dog(100%), Chicken(92%), Xenopus(83%)
Clonality:
Polyclonal
Specificity:
ORAI1 Antibody detects endogenous levels of total ORAI1.
RRID:
AB_2841354
Cite Format: Affinity Biosciences Cat# DF7956, RRID:AB_2841354.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Calcium release activated calcium channel protein 1; Calcium release activated calcium modulator 1; Calcium release-activated calcium channel protein 1; CRACM 1; CRACM1; CRCM1; CRCM1_HUMAN; FLJ14466; Orai 1; ORAI calcium release activated calcium modulator 1; orai1; ORAT1; Protein orai 1; Protein orai-1; TMEM 142A; TMEM142A; Transmembrane protein 142A;

Immunogens

Immunogen:
Uniprot:

Q96D31(CRCM1_HUMAN) >>Visit HPA database.

Gene(ID):
ORAI1(84876)
Sequence:
MHPEPAPPPSRSSPELPPSGGSTTSGSRRSRRRSGDGEPPGAPPPPPSAVTYPDWIGQSYSEVMSLNEHSMQALSWRKLYLSRAKLKASSRTSALLSGFAMVAMVEVQLDADHDYPPGLLIAFSACTTVLVAVHLFALMISTCILPNIEAVSNVHNLNSVKESPHERMHRHIELAWAFSTVIGTLLFLAEVVLLCWVKFLPLKKQPGQPRPTSKPPASGAAANVSTSGITPGQAAAIASTTIMVPFGLIFIVFAVHFYRSLVSHKTDRQFQELNELAEFARLQDQLDHRGDHPLTPGSHYA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
92
Rabbit
92
Xenopus
83
Zebrafish
75
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q96D31 As Substrate

Site PTM Type Enzyme
S19 Phosphorylation
S25 Phosphorylation
S27 Phosphorylation P05771 (PRKCB)
S30 Phosphorylation P05771 (PRKCB)
S34 Phosphorylation Q13976 (PRKG1)
S65 Phosphorylation
K78 Ubiquitination
T295 Phosphorylation
S298 Phosphorylation
Y300 Phosphorylation

Research Backgrounds

Function:

Ca(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1. CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT.

PTMs:

N-glycosylated.

Ubiquitinated.

Cys-195 is oxidated, leading to inactivate channel activity.

Subcellular Location:

Cell membrane>Multi-pass membrane protein.
Note: Isoform beta is more mobile in the plasma membrane (PubMed:23307288). Colocalizes with STIM1 at the cell membrane (PubMed:27185316).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Interacts with STIM1 and STIM2; this regulates channel activity. Interacts with CALM; this may displace STIM1 and STIM2 and might thereby modulate channel activity. Interacts with CRACR2A/EFCAB4B; the interaction is direct and takes place in absence of Ca(2+). Forms a complex with CRACR2A/EFCAB4B and STIM1 at low concentration of Ca(2+), the complex dissociates at elevated Ca(2+) concentrations. Interacts with ASPH (isoform 8). Interacts with SLC35G1. Interacts with UBQLN1. Interacts with ADCY8; interaction is calcium store depletion independent; interaction occurs in membrane raft; interaction increases markedly after store depletion; positively regulates SOCE-induced adenylate cyclase activity; contributes to the targeting of ADCY8 to discrete regions of the plasma membrane that are shielded from other calcium events. Interacts with EFHB; the interaction takes place upon Ca(2+)-store depletion.

Family&Domains:

Belongs to the Orai family.

Research Fields

· Environmental Information Processing > Signal transduction > Calcium signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Human Diseases > Immune diseases > Primary immunodeficiency.

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Endocrine system > Renin secretion.

· Organismal Systems > Endocrine system > Aldosterone synthesis and secretion.

References

1). Parathyroid Hormone Promotes Human Umbilical Vein Endothelial Cell Migration and Proliferation Through Orai1-Mediated Calcium Signaling. Frontiers in Cardiovascular Medicine (PubMed: 35369318) [IF=3.6]

Application: WB    Species: Human    Sample: HUVECs

Figure 1 Effects of parathyroid hormone (PTH) on Orai expression and proliferation of human umbilical vein endothelial cells (HUVECs). (A–D) Representative Western blot images (A) and summary data (B–D) showing Orai1, Orai2, and Orai3 expression level changes in HUVECs after PTH treatment (1, 10, 100 pM) for 24 h compared with the vehicle control (Con). (E) Summary data showing viability of HUVECs treated with PTH (100 pM) for 24 h. (F,G) Representative Western blot images (F) and summary data (G) showing STIM1 expression level changes in HUVECs after PTH treatment (1, 10, 100 pM) for 24 h compared with the vehicle control (Con). Data are shown as the mean ± SEM; n = 3–5. *P < 0.05, **P < 0.01 vs. Con analyzed by one-way analysis of variance followed by Dunnett's multiple comparisons test.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.